Chapter 3: 9.3

9.3: What topics are currently receiving attention in FDA news? What effect has the attention had on market share?

“Pfizer’s Camptosar Faces Generic Competition”

– Pfizer’s Chemotherapy agent, Camptosar, lost it’s patent last month and opens the door for competition. This will potentially reduce Pfizer’s share of the market as generic drug manufacturers can now bring the same product to the market at a much reduced rate. Overall, this will bring the cost of this specific drug down.


“UK’s MHRA Calls for Quicker Clinical Trial Safety Reporting”

– This will make the drug companies in the UK more accountable for reporting the safety signals to UK consumers. This can potentially drive the cost of drugs up worldwide but will, undoubtedly, increase the safety of new drugs as they come to the market. In addition, this increased safety make put more consumers at ease in the long run and actually strengthen consumer confidence in their brand.


“Solvay Gets Good and Bad News From Partners”

– The good news for Solvay was that the FDA approved two new drugs to treat various mental illnesses. This will increase supply of these types of pharmaceuticals in the market and drive up competition for consumers. The bad news for them was that they lost a $20M partnership from Wyeth to develop two new treatments for other mental illnesses. This will be a blow to the company and will hurt future operations but will not immediately have much impact on the market.